10
Participants
Start Date
February 28, 2011
Primary Completion Date
December 31, 2014
Study Completion Date
January 31, 2015
Ranolazine
Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
Placebo
Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
University of California, San Diego, San Diego
Collaborators (1)
Gilead Sciences
INDUSTRY
University of California, San Diego
OTHER